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Conventional smallpox vaccines based on replicating vaccinia virus (VV) strains (e.g. Lister
Elstree, NYCBOH) are associated with a high incidence of myo-/pericarditis, a severe
inflammatory cardiac complication. A new smallpox vaccine candidate based on a non-
replicating Modified Vaccinia Ankara (MVA) poxvirus has been assessed for cardiac safety
in a large placebo-controlled clinical trial.
Methods
Cardiac safety of one and two doses of MVA compared to placebo was assessed in 745
healthy subjects. Vaccinia-naïve subjects received either one dose of MVA and one dose of
placebo, two doses of MVA, or two doses of placebo by subcutaneous injection four weeks
apart; vaccinia-experienced subjects received a single dose of MVA. Solicited and unsolicit-
ed adverse events (AE) and cardiac safety parameters (recorded as Adverse Events of
Special Interest, AESI) were monitored after each injection.
Results
A total of 5 possibly related AESI (3 cases of palpitations, 2 of tachycardia) were reported
during the study. No case of myo- or pericarditis occurred. One possibly related serious AE
(SAE) was reported during the 6-month follow-up period (sarcoidosis). The most frequently
observed AEs were injection site reactions.
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Due to the eradication of smallpox in 1980 and discontinuation of smallpox vaccinations
worldwide, an increasing majority of the global population has no existing immunity to Variola
virus (VARV). As the release of this highly contagious virus would have devastating effects, the
potential use of VARV as an agent in bioterrorism or bio-warfare has raised significant con-
cerns. Thus, many governments recognize the need for a safe and efficacious smallpox vaccine
to secure public health interests.
MVA is a highly attenuated strain of VV that fails to replicate in human cells [1] and there-
fore cannot be transmitted or cause disseminated VV infection, which is an important safety
concern of conventional smallpox vaccines[2–4]. Conventional vaccines are also associated with
severe adverse events, including myo-/pericarditis or even death [3,5,6]. During the US National
Smallpox Pre-Event Vaccination Programs initiated in 2002–2004, an unexpected high inci-
dence of myo-/pericarditis was detected in close temporal relationship to Dryvax administration
(> 1:10,000), which was notably higher than the expected rate in non-vaccinated US military
personnel (0.21:10,000) [7–13]. In addition to clinical symptoms indicative of a cardiac event,
criteria for diagnosis of suspected myo-/pericarditis included elevated serum levels of cardiac
enzymes (CK-MB, troponin), usually in the presence of ST-segment elevation on ECG, and wall
motion abnormalities on echocardiogram[14]. The vast majority of cases occurred within the
first 14 days post-vaccination. Most subjects presented initially with chest pain or prodromal
clinical symptoms including fever, chills, myalgia, arthralgia, and headache[15–17].
Moreover, a remarkably high number of suspected and probable myo-/pericarditis cases
were reported in the pivotal clinical program of the second generation smallpox vaccine
ACAM2000 [18]. In contrast to the national vaccination programs where cases were identified
when symptomatic vaccinees presented for medical evaluation, the ACAM2000 trials included
active post-vaccination cardiac monitoring, leading to detection of 8 myo-/pericarditis cases
in 1,162 primary vaccinees after vaccination with either ACAM2000 or Dryvax (incidence of
1:145). Most cases were symptomatic (i.e. subjects presented with chest pain, reduced tolerance
to exercise, dyspnea or palpitations) and diagnosis was confirmed by coexisting ECG changes
and/or echocardiogram, findings indicative of myocardial inflammation.
Based on this experience, a causal association between conventional smallpox vaccines and
myo-/pericarditis has been postulated, although the pathomechanism for cardiotoxicity re-
mains unclear[13]. This has led to the inclusion of close cardiac monitoring in clinical develop-
ment programs for poxvirus based smallpox vaccines like MVA.
BN has performed a large placebo-controlled Phase II study to determine immunogenicity
and safety of MVA with special focus on cardiac safety. Monitoring of ECG changes, new onset
of cardiac symptoms and increase of cardiac enzymes was performed to assess the potential
risk of developing myo-/pericarditis after vaccination with MVA.
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Material and Methods
The protocol for this study and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol.
Vaccine
The MVA strain was derived from the MVA vaccine licensed in Germany by additional pas-
sages and serial dilutions in chicken embryo fibroblast (CEF) cells[5,6]. MVA smallpox vaccine
was produced by IDT Biologika GmbH (Dessau-Roßlau, Germany) according to GMP and
provided by Bavarian Nordic A/S (Kvistgaard, Denmark) in aliquots of 0.5 ml liquid-frozen
vaccine containing at least 1 x 108 TCID50 (Tissue Culture Infectious Dose 50) /ml.
Participants and Study Procedures
The study was performed at a Clinical Research Organization in compliance with current stan-
dards of the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use—Good Clinical Practice (ICH-GCP), the Dec-
laration of Helsinki and local legal and regulatory requirements. A total of 1,322 volunteers be-
tween 18 and 55 years of age were screened (Table 1). Healthy subjects with normal baseline
ECG, cardiac troponin I within normal limits and no active or history of cardiac disease were
eligible for inclusion in the study.
Subjects with coronary heart disease, myocardial infarction, angina, congestive heart failure,
cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, any
other medically treated heart condition, a family history of death due to ischemic heart disease
Table 1. Demographics.
Group 1 (MM) vaccinia-
naïve (N = 183)
Group 2 (MP) vaccinia-
naïve (N = 181)
Group 3 (PP) vaccinia-
naïve (N = 181)
Group 4 (M-) vaccinia-
exp. (N = 200)
Age [years] Mean 25.3 25.4 26.0 41.5
SD 5.0 4.4 5.1 7.6
Median 24 25 25 42
Min 18 18 18 22
Max 50 44 50 55
BMI [kg/m2] Mean 23.6 23.7 23.9 24.6
SD 3.86 3.41 4.31 3.93
Median 23.0 23.2 23.1 23.9
Min 17.5 17.4 16.2 17.6
Max 46.7 35.8 46.5 40.7
Gender (n/%) Male 86 (47.0) 69 (38.1) 74 (40.9) 85 (42.5)
Female 97 (53.0) 112 (61.9) 107 (59.1) 115 (57.5)
Ethnic group
(n/%)
Caucasian 178 (97.3) 176 (97.2) 177 (97.8) 198 (99.0)
Asian 1 (0.5) 2 (1.1) 1 (0.6) 0 (0.0)
Black 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.5)
Arabic 2 (1.1) 1 (0.6) 1 (0.6) 0 (0.0)
Other 2 (1.1) 1 (0.6) 2 (1.1) 1 (0.5)
MM = two vaccinations with MVA; MP = first vaccination with MVA, second vaccination with placebo; PP = two vaccinations with placebo; M- = single
vaccination with MVA; BMI = body mass index; N = Number of subjects in each group; n = Number of subjects with data available; % = Percentage based
on N; SD = Standard deviation
doi:10.1371/journal.pone.0122653.t001
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before age 50 and/or a 10 percent risk for myocardial infarction or coronary death within
the next 10 years were excluded. Exclusionary ECG findings included any kind of atrioventric-
ular or intraventricular conditions or blocks such as complete left or right bundle branch
block, AV node block, QTc or PR prolongation; premature atrial contractions or other atrial
arrhythmia, sustained ventricular arrhythmia, two premature ventricular contractions (PVC)
in a row; ST elevation consistent with ischemia.
The study was approved by the ethics committee of the Ludwig-Maximilians-Universitaet,
Munich, Germany, under the approval number 365–05. Written informed consent was obtained
from all subjects. Seven hundred and forty-five (745) subjects were assigned to four groups
(Fig 1): Subjects with no history of previous smallpox vaccination (vaccinia-naïve) were randomly
assigned to Groups 1 to 3 to receive (under double-blind conditions, including subject handling,
trial personnel and data analysis) either two subcutaneous (s.c.) injections of MVA, one dose of
MVA and one dose of placebo or two doses of placebo, respectively. Group 4 (open-label) con-
sisted of subjects with a history of previous smallpox vaccination (vaccinia-experienced) that
Fig 1. Consolidated Standards of Reporting Trials (CONSORT) subject flow diagram demonstrating
the number of patients recruited into the study, number of subjects randomized and vaccinated, and
number of subjects analyzed.MVA: Modified Vaccinia Ankara; FAS: full analysis set: PP: per protocol
doi:10.1371/journal.pone.0122653.g001
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received a single vaccination with MVA. Enrolment started in April 2006, the last follow-up visit
was performed in August 2007.
Safety Assessments
Safety laboratory tests, including troponin I and ECGs were performed at the screening visit
and 10–15 days after each vaccination, and 28 to 35 days after the second (Groups 1–3) or sin-
gle vaccination (Group 4), as well as at the 6-month follow-up visit, if clinically indicated. All
subjects were monitored for ECG changes and cardiac symptoms, such as chest pain, shortness
of breath and palpitations, by a physical examination at all trial visits including heart and lung
auscultation specifically looking for heart failure, presence of rubs, gallops, murmurs, crackles,
and rales.
ECGs were evaluated by the investigator and transmitted electronically to a central database.
Subjects with abnormal ECG findings were referred to a cardiologist, which included a thor-
ough examination and performance of an echocardiogram and/or treadmill ECG.
Any cardiac symptom, clinically significant ECG changes or elevated cardiac enzymes (spe-
cifically troponin I above upper limit of normal [ULN]) were recorded as an adverse event of
special interest (AESI) and followed-up thoroughly to identify or rule-out any cardiac abnor-
malities. The case definitions as published by the US Center of Disease Control (CDC) [14]
were applied to recognize possible cases of acute myocarditis and pericarditis and to distinguish
unspecific and isolated ECG changes without or with unclear clinical meaning and ECG
changes related to possible or probable cases of acute myocarditis and/or pericarditis.
Unsolicited AE were recorded by the investigator at every study visit by asking the subject
for any change in health status since the last visit. Solicited local and general AE (injection site
erythema, swelling and induration as well as increased body temperature, headache, myalgia,
nausea and fatigue) and any additional symptoms were recorded by the subjects on a diary on
the day of vaccination and for the following 7 days, or longer, if lasting beyond the 7-day peri-
od. AEs not resolved at the last visit were followed-up and any potentially new SAE and AESI
were recorded at the follow-up visit.
Statistical Methods
ECGs were evaluated by a centralized ECG laboratory. Standard ECG results like PQ, QRS, QT
and QTc durations and formations as well as heart rate were summarized per visit and group.
Occurrence, relationship and intensity of ECG changes and any other cardiac symptom at
any time during the study were assessed and compared between groups by means of the exact
test of Fisher. The comparison of the four treatment groups with regard to ECG changes and
cardiac symptoms was the primary safety objective of this trial.
Detailed QTc analysis was performed according to FDA/EMA guidance [19]. PR, QT and
QRS durations as well as the reported QTc duration based on the Bazett correction, and heart
rate were tabulated per group and visit.
AESI were defined as any cardiac symptom, clinically significant ECG changes or cardiac
enzymes elevated above the ULN, and were separately listed and tabulated; incidence was com-
pared between groups taking Group 3 (placebo) as the reference group by means of the exact
test of Fisher. Here the following commonly used classification of significance was used to dis-
play the results: NS = Not Significant (i.e. p0.05);  p< 0.05;  p<0.01;  p< 0.001).
Unsolicited AE were coded using the MedDRA coding terminology and graded based on in-
tensity. The number of AE and number of subjects with at least one AE for each preferred term
were descriptively compared between groups. The occurrence of any Grade 3 or higher AE
Cardiac Safety of Modified Vaccinia Ankara for Smallpox Vaccination
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possibly, probably or definitely related to the study vaccine within 28 days after vaccination was
compared between groups.
Occurrence and intensity of solicited general AE within one week after each vaccination was
summarized per patient and vaccination. Occurrence and intensity of solicited local AE were
documented and graded according to maximum severity. The maximum intensity over the
7-day period after vaccination was used, categorized as Grades 1 to 4 and compared between
groups groups using Group 3 as the reference group by means of Fisher’s exact test.
SAE were listed separately and individually described. The number of subjects with at least
one SAE was compared between groups using Group 3 as the reference group by means of
Fisher’s exact test.
Results
Participants and Demographic Data
Data of 745 randomized subjects who were administered at least one vaccination (564 with
MVA and 181 with placebo) were included in the analysis (Fig 1). Of the vaccinia-naïve sub-
jects, 180 subjects (Group 1) received two doses of MVA and three subjects from Group 1 as
well as 181 subjects from Group 2 received a single dose of MVA. 174 subjects in Group 2 re-
ceived placebo with the second injection. 200 vaccinia-experienced subjects received a single
dose of MVA (Group 4).
There were slightly more female than male subjects in all groups (Table 1). The vaccinia-
naïve population was younger than the vaccinia-experienced population. The median body
mass index (BMI) between groups was similar.
Cardiac Monitoring
To ensure that subjects did not have any cardiac abnormalities prior to enrollment, all subjects
received an ECG assessment at screening. All ECGs were assessed by the investigator and a
central ECG laboratory, and any abnormal or unclear findings were further assessed by a cardi-
ologist. Of the 745 enrolled subjects, 324 (43.5%) had initial ECGs which led to a more thor-
ough cardiac work-up. The ECGs from all enrolled subjects were ultimately assessed to be
normal, of these 358 (48.1%) normal ECGs and 386 (51.6%) had ECGs with normal variations
such as sinus arrhythmia.
A total of 11 AESI were reported for 10 subjects during the active phase (successful screen-
ing until 28 days after last vaccination) of the study. The reported events were palpitations,
tachycardia and sinus tachycardia, of which 5 events in 4 subjects were considered as possibly
related to the study vaccine (Tables 2 and 3). A further five AESI were reported during follow-
up (later than 28 days after last vaccination until end of trial) in five subjects consisting of pal-
pitations, tachycardia and mild pericardial effusion, all assessed as unlikely related.
Subjects showing any ECG abnormalities at any of the post-vaccination visits underwent a
thorough cardiac work-up by a cardiologist. Nearly one third of all subjects received echocar-
diograms and/or treadmill ECGs during the study and all examinations completely ruled out
any cardiac abnormalities. Table 4 summarizes all ECG abnormalities observed by group and
by visit. Approxinately 20–30% of subjects in each group with normal ECGs at baseline had
ECG changes at visit 2 consistent with normal variation and approximately 20–30% of subjects
with ECGs demonstrating normal variation at baseline had normal ECGs at visit 2 (Table 4).
Similar percentages of subjects with ECG changes were observed at Visit 4, whereby nearly half
had reverted back to the original screening assessment.
Despite the unexpectedly large number of subjects with ECG findings which triggered
further work-up, all ECG recordings were ultimately assessed by the investigator and/or the
Cardiac Safety of Modified Vaccinia Ankara for Smallpox Vaccination
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cardiologist to be normal or represent normal variations. No significant QTc prolongations
nor changes in PR, QRS and/or RR intervals were considered related to vaccination. Differ-
ences in the rates of normal ECGs between the active treatment groups versus placebo were
not significant for groups 1 and 2, and showed more normal ECGs than in the placebo group
for group 4 (Vaccinia experienced subjects). There were no differences between groups includ-
ing placebo with regard to ECG changes and cardiac symptoms and no cases of myo- or peri-
carditis were reported.
Solicited and unsolicited Adverse Events
A total of 718 AEs were reported during the active study phase. The majority of unsolicited
AEs were mild or moderate (Grades 1 and 2); of the 18 cases documented as severe (Grade 3),
only chills and injection site urticaria were assessed as related to study vaccine. Furthermore,
there were no vaccine-related clinically significant laboratory abnormalities.
During the active phase of the study, three SAEs were reported which were assessed as
unrelated (ruptured finger tendon) or unlikely related (nervous breakdown, transient motoric
hemiparesis) to the study vaccine. The case of transient motoric hemiparesis occurred in a
38-year old female subject 6 days after the first vaccination and was judged by the investigator
to be unlikely related to study vaccine but rather related to a previous history of migraine
accompagnée,
During the 6-month follow up, nine SAEs were reported, thereof for one (sarcoidosis, diag-
nosed by bronchoscopy and biopsy), a causal relationship could not be ruled out. Ten weeks
following the second vaccination with MVA, a 30 year old, otherwise healthy male subject con-
tracted a urinary tract infection (Chlamydia trachomatis), which was treated with antibiotics.
Concomitant arthralgia and fever continued, leading to a chest x-ray, bronchoscopy and finally
the diagnosis of sarcoidosis. The responsible Data Safety Monitoring Board members assessed
the event to be unlikely related to vaccination and expressed no concerns regarding continua-
tion of the MVA development program. Two further SAEs, colon carcinoma and depression,
Table 2. Overview of Unsolicited Adverse Events per Subject.
Subject based Group 1 Group 2 Group 3 Group 4
(MM) (MP) (PP) (M/-)
vaccinia-naïve vaccinia-naïve vaccinia-naïve vaccinia-exp.
(N = 183) (N = 181) (N = 181) (N = 200)
SAE 3 (1.6) NS 2 (1.1) NS 5 (2.8) 1 (0.5) NS
Possibly related SAE* 1 (0.5) NS 0 (0.0) NS 0 (0.0) 0 (0.0) NS
AESI 3 (1.6) NS 4 (2.2) NS 1 (0.6) 8 (4.0) *
Possibly related AESI 0 (0.0) NS 2 (1.1) NS 0 (0.0) 2 (1.0) NS
At least one unsolicited AE 113 (61.7) *** 107 (59.1) ** 78 (43.1) 99 (49.5) NS
Related unsolicited AE 61 (33.3) *** 61 (33.7) *** 23 (12.7) 74 (37.0) ***
Related unsolicited AE  Grade 3 4 (2.2) NS 8 (4.4) NS 4 (2.2) 1 (0.5) NS
AE leading to withdrawal from study 0 (0.0) NS 1 (0.6) NS 1 (0.6) 0 (0.0) NS
AE = adverse event (up to 28 days after the first vaccination); SAE = serious adverse event (up to 6 months after the last vaccination); AESI = adverse
event of special interest (cardiac event; up to 6 months after the last vaccination); * reported during the 6-month follow-up period. Fishers Exact test of
comparison to Group 3; NS = Not Significant (p0.05);
* p< 0.05;
** p<0.01;
*** p < 0.001).
doi:10.1371/journal.pone.0122653.t002
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were judged to be unlikely related to vaccination, while the remaining were considered to be
not related.
Solicited general as well as local symptoms were generally moderate in severity and none
were considered life-threatening or disabling (Grade 4). Table 5 shows related AEs with a fre-
quency of2% in at least one study group. Most AEs belong to the System Organ Class (SOC)










Duration Other conditions Cardiac work-up/
safety lab
Outcome




Unlikely 14 days Minutes Thyroxin treatment for
hypothyreosis





Unlikely 31 days 4 months Psychological stress TSH, T3, T4 (normal) Recovered





Group 2 (MP) vaccinia-naïve (N = 181)













Possibly 28 days 2 days Nervousness, pre-




Unlikely 193 days intermittent Personal distress - Ongoing
Group 3 (PP) vaccinia-naïve (N = 181)
689 Palpitations Unlikely 23 days intermittent Recurrent pain in
shoulder
- Ongoing
Group 4 (M-) vaccinia-exp. (N = 200)
024 Palpitations
(FU)
Unlikely >90 days intermittent Anxiety, depression - Recovered
028 Palpitations Possibly 3 hours 1 hour Sweating - Recovered










Unlikely 182 days 13 days Nervousness Echocardiogram,





Possibly ~ 4 hours 3 days Nervousness TSH, T3, T4 (normal) Recovered













Bpm = beats per minute (heart rate); HR = heart rate; Adverse events of special interest (AESI) that were reported during the half-year follow-up phase
are marked with “FU”
doi:10.1371/journal.pone.0122653.t003
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Table 4. Summary of ElectrocardiogramAbnormalities (Safety Analysis Set, N = 745).
Group 1 Group 2 Group 3 Group 4
n (%) N = 183 n (%) N = 181 n (%) N = 181 n (%) N = 200
Screening
Assessment missing 0 0 0 0
Normal 87 (47.5%) NS 78 (43.1%) NS 76 (42.0%) 118 (59.0%) **
Abnormal, CS 0 0 0 0
Abnormal, NCS 96 (52.5%) 103 (56.9%) 105 (58.0%) 82 (41.0%)
AV block (PQ time > 0.20 sec)—first degree 0 0 1 (0.6%) 1 (0.5%)
Right bundle branch block—incomplete 10 (5.5%) 18 (9.9%) 4 (2.2%) 1 (0.5%)
ST elevation 5 (2.7%) 1 (0.6%) 4 (2.2%) 1 (0.5%)
ST depression 0 1 (0.6%) 0 1 (0.5%)
T inversion—pathological 42 (23.0%) 54 (29.8%) 50 (27.6%) 48 (24.0%)
T inversion—other 14 (7.7%) 19 (10.5%) 22 (12.2%) 16 (8.0%)
Low voltage 0 0 0 1 (0.5%)
Other* 23 (12.6%) 23 (12.7%) 26 (14.4%) 5 (2.5%)
Bradycardia 30 (16.4%) 28 (15.5%) 30 (16.6%) 6 (3.0%)
Arrhythmia 4 (2.2%) 3 (1.7%) 8 (4.4%) 1 (0.5%)
Repolarisation 3 (1.6%) 3 (1.7%) 3 (1.7%) 0
Q-Abnormalities 1 (0.5%) 1 (0.6%) 0 4 (2.0%)
Tall T-waves 0 0 0 0
Two weeks post vaccination 1
Assessment missing 1 (0.5%) 2 (1.1%) 2 (1.1%) 0
Normal 91 (49.7%) NS 81 (44.8%) NS 84 (46.4%) 129 (64.5%) ***
Abnormal, CS 0 0 0 0
Abnormal, NCS 91 (49.7%) 98 (54.1%) 95 (52.4%) 71 (35.5%)
Supraventricular arrhythmia 0 1 (0.6%) 0 0
Ventricular arrhythmia 0 1 (0.6%) 1 (0.6%) 0
AV block (PQ time > 0.20 sec)—first degree 0 0 1 (0.6%) 1 (0.5%)
Right bundle branch block—incomplete 9 (4.9%) 17 ((9.4%) 15 (8.3%) 15 (7.5%)
ST elevation 3 (1.6%) 1 (0.6%) 2 (1.1%) 0
ST depression 0 1 (0.6%) 1 (0.6%) 1 (0.5%)
T inversion—pathological 34 (18.6%) 46 (25.4%) 40 (22.1%) 31 (15.5%)
T inversion—other 11 (6.0%) 9 (5.0%) 10 (5.5%) 7 (3.5%)
Other* 34 (18.6%) 29 (16.0%) 34 (18.8%) 14 (7.0%)
Bradycardia 31 (16.9%) 25 (13.8%) 33 (18.2) 6 (3.0%)
Arrhythmia 4 (2.2%) 4 (2.2%) 2 (1.1%) 5 (2.5%)
Repolarisation 1 (0.5%) 3 (1.7%) 2 (1.1%) 1 (0.5%)
Q-Abnormalities 0 3 (1.7%) 1 (0.6%) 4 (2.0%)
Tall T-waves 1 (0.5%) 3 (1.7%) 0 0
Two weeks post vaccination 2
Assessment missing 7 (3.8%) 7 (3.9%) 6 (3.3%) NA
Normal 89 (48.6%) NS 82 (45.3%) NS 82 (45.3%)
Abnormal, CS 0 0 0
Abnormal, NCS 87 (47.5%) 92 (50.1%) 93 (51.4%)
Supraventricular arrhythmia 1 (0.5%) 1 (0.6%) 0
AV block (PQ time > 0.20 sec)—first degree 2 (1.1%) 0 1 (0.6%)
Right bundle branch block—incomplete 10 (5.5%) 20 (11.0%) 12 (6.6%)
ST elevation 1 (0.5%) 3 (1.7%) 1 (0.6%)
(Continued)
Cardiac Safety of Modified Vaccinia Ankara for Smallpox Vaccination
PLOS ONE | DOI:10.1371/journal.pone.0122653 April 16, 2015 9 / 14
“General disorders and administration site conditions”. As expected, a clear difference between
placebo and MVA was observed: 98.9%, 97.8% and 97.0% of subjects in Groups 1, 2 and 4 had
at least one vaccine-related solicited or unsolicited AE, respectively, compared to 56.9% receiv-
ing placebo. Local injection site reactions such as pain, erythema, induration, swelling, pruritus
and warmth presented with a significantly lower frequency in the placebo group and indicate a
direct relationship to vaccination with MVA compared to placebo. Nevertheless, pain and ery-
thema did still occur in 20.4% and 21.5%, respectively, of subjects receiving placebo.
When comparing Group 1 with Group 3, fatigue, headache, myalgia and nasopharyngitis
occurred slightly less frequently in the placebo group (Table 5). Comparing Group 2 with
Group 3, fatigue and myalgia were similarly frequent (23.2% vs. 24.9% and 7.7% vs. 8.3%, re-
spectively). The highest incidence of fatigue and myalgia was observed in subjects in Group 4
(35.5% and 19.5%, respectively).
Overall, there were significantly more AEs in the active treatment groups versus placebo.
However, the AE profile was consistent with that of other, approved live-attenuated vaccines.
Discussion
The primary safety objective of this study was to compare the four vaccination groups with re-
gard to ECG changes and cardiac symptoms. Despite rigorous cardiac monitoring of all sub-
jects enrolled in this trial, no cardiac safety signals including cardiac enzyme elevations such as
troponin I were detected, reported neither as cardiac symptoms nor as abnormal ECG record-
ings. Not a single case of myo-/pericarditis was reported following vaccination with MVA, in
contrast to the high incidence of myo-/pericarditis observed with Dryvax (10.38 events per
thousand vaccinations) and ACAM2000 (5.73 events per thousand immunizations)[20].
Screening revealed an unexpectedly high rate of “abnormal” ECGs in this young healthy popu-
lation. Of the 543 subjects that failed screening, 139 could not be enrolled due to abnormal ECG
findings. Furthermore, routine ECGs performed at visits following the vaccinations also resulted
Table 4. (Continued)
Group 1 Group 2 Group 3 Group 4
n (%) N = 183 n (%) N = 181 n (%) N = 181 n (%) N = 200
ST depression 1 (0.5%) 0 0
T inversion—pathological 28 (15.3%) 37 (20.4%) 39 (21.5%)
T inversion—other 3 (1.6%) 5 (2.8%) 4 (2.2%)
Other* 35 (19.1%) 35 (19.3%) 33 (18.2%)
Bradycardia 30 (16.4%) 23 (12.7%) 28 (15.5%)
Arrhythmia 4 (2.2%) 4 (2.2%) 2 (1.1%)
Repolarisation 2 (1.1%) 3 (1.7%) 7 (3.9%)
Q-Abnormalities 1 (0.6%) 0 1 (0.6%)
Tall T-waves 1 (0.6%) 1 (0.6%) 2 (1.1%)
N = number of subjects in each group, % = percentage based on N. NA = not applicable; AV = atrioventricular, CS = clinically significant, NCS = not
clinically significant, PQ = PQ interval in electrocardiogram, QTc = QT interval corrected for hart rate, ST = ST segment in electrocardiogram,
*Other: non-specific ECG findings not consistent with one of the terms specified in this table
This table includes ECGs obtained in routine study visits only, but no ECGs obtained in potential further workups.
Fishers Exact test of comparison to Group 3; NS = Not Significant (p0.05);
* p< 0.05;
** p<0.01;
*** p < 0.001).
doi:10.1371/journal.pone.0122653.t004
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in large numbers of falsely abnormal findings. Extensive cardiac work-up did not reveal any true
cardiac condition in all cases. Therefore, it seems that normal variations, rather than cardiac ab-
normalities were actually being measured. Even in young and healthy individuals, ECG screening
frequently reveals abnormalities such as right bundle branch block, fascicular block, first-degree
AV blocks or non-specific T-wave abnormalities[21]. When performing routine measurements
Table 5. Related Adverse Events with a frequency of2% in at least one study group; MedDRACoding by SystemOrgan Class and Preferred
Term (Safety dataset).
N = Number of subjects in the specified group
SOC Preferred Term (PT) Group 1 (N = 183) Group 2 (N = 181) Group 3 (N = 181) Group 4 (N = 200)
Number of subjects (%)—Number of events
General disorders and administration site conditions
Any PT 181 (98.9) 1392 *** 177 (97.8) 824 *** 103 (56.9) 252 194 (97.0) 894 ***
Injection site pain 166 (90.7) 300 155 (85.6) 168 37 (20.4) 46 167 (83.5) 167
Injection site erythema 166 (90.7) 304 146 (80.7) 160 39 (21.5) 51 169 (84.5) 169
Injection site induration 162 (88.5) 273 146 (80.7) 155 5 (2.8) 6 155 (77.5) 155
Injection site swelling 149 (81.4) 247 103 (56.9) 112 10 (5.5) 12 149 (74.5) 149
Fatigue 57 (31.1) 75 42 (23.2) 52 45 (24.9) 53 71 (35.5) 71
Headache 42 (23.0) 49 58 (32.0) 66 31 (17.1) 36 51 (25.5) 51
Injection site pruritus 43 (23.5) 61 36 (19.9) 37 4 (2.2) 4 47 (23.5) 47
Myalgia 23 (12.6) 24 15 (8.3) 15 14 (7.7) 18 39 (19.5) 39
Body temperature increased 16 (8.7) 18 19 (10.5) 19 10 (5.5) 10 10 (5.0) 10
Nausea 12 (6.6) 14 17 (9.4) 20 8 (4.4) 8 16 (8.0) 16
Injection site hematoma 6 (3.3) 6 9 (5.0) 9 4 (2.2) 4 4 (2.0) 4
Injection site warmth 9 (4.9) 9 5 (2.8) 5 0 (0.0) 0 8 (4.0) 8
Injection site discoloration 1 (0.5) 1 4 (2.2) 4 0 (0.0) 0 0 (0.0) 0
Nervous system disorders
Any PT 1 (0.5) 1 6 (3.3) 6 3 (1.7) 3 6 (3.0) 7
Dizziness 1 (0.5) 1 2 (1.1) 2 2 (1.1) 2 4 (2.0) 4
Infections and infestations
Any PT 6 (3.3) 7 1 (0.6) 1 5 (2.8) 6 2 (1.0) 3
Nasopharyngitis 5 (2.7) 5 0 (0.0) 0 4 (2.2) 4 1 (0.5) 1
Gastrointestinal disorders
Any PT 2 (1.1) 3 1 (0.6) 1 2 (1.1) 3 7 (3.5) 7
Diarrhoea 0 (0.0) 0 1 (0.6) 1 1 (0.6) 1 4 (2.0) 4
Respiratory, thoracic and mediastinal disorders
Any PT 2 (1.1) 2 2 (1.1) 2 2 (1.1) 2 5 (2.5) 5
Pharyngolaryngeal pain 2 (1.1) 2 1 (0.6) 1 1 (0.6) 1 4 (2.0) 4
Blood and lymphatic system disorders
Any PT 2 (1.1) 4 5 (2.8) 5 0 (0.0) 0 2 (1.0) 2
Lymphadenopathy 2 (1.1) 3 NS 4 (2.2) 4 NS 0 (0.0) 0 2 (1.0) 2 NS
Vascular disorders
Any PT 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 4 (2.0) 4
Hot flush 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 4 (2.0) 4
Fishers Exact test of comparison to Group 3; NS = Not Significant (p0.05);
* p< 0.05;
** p<0.01;
*** p < 0.001).
doi:10.1371/journal.pone.0122653.t005
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of ECGs in presumably healthy subjects, one therefore has to consider a potentially high level of
background noise [22,23]. This questions whether an ECG represents an appropriate criterion to
determine subject eligibility for clinical trials, particularly in healthy young populations. In addi-
tion, control ECGs performed throughout ongoing studies without accompanying cardiac symp-
toms or other clinical signs can lead to the necessity of communicating (falsely) abnormal ECG
findings to the volunteers, as was the case in this study. This inevitably leads to anxiety as well as
time- and resource-consuming cardiac work up for ruling out any true cardiac condition. Particu-
larly in vaccine studies, which generally by default enroll only healthy volunteers, the often con-
founding and misleading results of routine ECGmonitoring seem to outweigh the benefits.
Exceptions are of course vaccines known to cause cardiac complications, such as replication-com-
petent smallpox vaccines [15–17]. For the non-replicating MVA vaccine no confirmed cases of
severe cardiac events have been reported in the clinical development program[24–31].
Similar to performing ECGs without a clinical indication, however, the value of routine tro-
ponin I measurements in the absence of cardiac symptoms has also been questioned. There are
reports that many factors can lead to falsely positive troponin values [32–34]. Furthermore, it
is known that isolated elevated troponin I does not necessarily correlate with cardiac damage
[35]. Therefore, routine troponin I measurements within the context of a clinical trial have to
be regarded as a screening parameter only, as any observed abnormality requires a thorough
cardiologist workup to confirm a clinically significant cardiac finding.
Secondary safety objectives of this study were comparisons with regard to overall safety of
the four vaccination groups and specifically of Groups 1 and 2 with the placebo group (Group
3) in vaccinia-naive subjects. Commonly observed AEs in this study were local symptoms
(pain, erythema, induration and swelling) at the injection site and general symptoms, such as
fatigue, headache and myalgia. The significantly lower frequency of local symptoms in the pla-
cebo group was expected as these AE are known to be associated with injectable vaccines such
as MVA. By far the majority of local symptoms were mild or moderate. Only 3.3% or less of
the subjects in any group had Grade 3 local reactions and no Grade 4 events were reported.
None of the SAE historically associated with replicating smallpox vaccines, such as Dryvax
or ACAM2000 [7,11–13,36], were reported in this study. Thus, the large amount of safety data,
including extensive cardiac monitoring results, collected from the 745 subjects who completed
this study confirm the excellent safety and tolerability profile of MVA. The results revealed no
safety concerns in this healthy study population, particularly with regard to the development of
cardiac events following vaccination with MVA. A Phase III clinical trial evaluating the cardiac
safety of MVA in 3,000 subjects compared to placebo is currently ongoing and expected to pro-
vide further confirmative data in this regard.
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